DR info

臨床試験数 : 29 / 薬物数 : 47 - (DrugBank : 29) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 119

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Bortezomib
   Washington University School of Medicine
      2010   Phase 1/Phase 2   NCT01000285   United States;
Ciclosporin
   Imperial College London
      2006   Phase 2/Phase 3   NCT00773292   United Kingdom;
Costicosteroids
   University of Sao Paulo
      2008   Phase 3   NCT00681980   Brazil;
Cyclophosphamide
   AIDS Malignancy Consortium
      2002   Phase 2   NCT00041327   United States;
   National Cancer Institute (NCI)
      2020   Phase 1   NCT04301076   United States;
   Washington University School of Medicine
      2010   Phase 1/Phase 2   NCT01000285   United States;
Doxorubicin
   Washington University School of Medicine
      2010   Phase 1/Phase 2   NCT01000285   United States;
Doxorubicin Hydrochloride
   National Cancer Institute (NCI)
      2020   Phase 1   NCT04301076   United States;
Doxorubicin hydrochloride
   AIDS Malignancy Consortium
      2002   Phase 2   NCT00041327   United States;
Etoposide
   AIDS Malignancy Consortium
      2002   Phase 2   NCT00041327   United States;
   National Cancer Institute (NCI)
      2020   Phase 1   NCT04301076   United States;
   Washington University School of Medicine
      2010   Phase 1/Phase 2   NCT01000285   United States;
Filgrastim
   AIDS Malignancy Consortium
      2002   Phase 2   NCT00041327   United States;
Hu MiK-Beta-1
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 1   NCT00076843   United States;
KW-0761
   Kyowa Hakko Kirin Co., Ltd.
      2017   Phase 3   JPRN-JapicCTI-173608   -
   Kyowa Kirin Co., Ltd
      2017   Phase 3   JPRN-JMA-IIA00324   Japan;
KW-0761 0.3 mg/kg IV
   Kyowa Kirin Co., Ltd.
      2017   Phase 3   NCT03191526   Japan;
Lamivudine
   AIDS Malignancy Consortium
      2002   Phase 2   NCT00041327   United States;
Lenalidomide
   Columbia University
      2010   Phase 2   NCT01274533   United States;
   National Cancer Institute (NCI)
      2020   Phase 1   NCT04301076   United States;
MT-3921
   Mitsubishi Tanabe Pharma Corporation
      2022   Phase 1   NCT05240612   -
Methylprednisolone
   St. Marianna University School of Medicine Hospital
      2016   Phase 2,3   JPRN-UMIN000023798   Japan;
      2016   -   JPRN-UMIN000024086   Japan;
Mogamulizumab
   Japan Agency for Medical Research and Development
      2015   Phase 1   JPRN-UMIN000016683   Japan;
   Kyowa Hakko Kirin Co., Ltd.
      2017   Phase 3   JPRN-JapicCTI-173608   -
Nivolumab
   Mayo Clinic
      2017   Phase 2   NCT03075553   United States;
   National Cancer Institute (NCI)
      2017   Phase 2   NCT02631746   United States;
Pentosan polysulfate
   ReqMed Company, Ltd
      2014   Phase 2   JPRN-UMIN000015587   Japan;
Pentoxifylline
   Hospital Universitário Professor Edgard Santos
      2009   Phase 3   NCT01472263   Brazil;
Prednisolone
   St. Marianna University School of Medicine Hospital
      2016   Phase 2,3   JPRN-UMIN000024085   Japan;
      2016   Phase 2,3   JPRN-UMIN000023798   Japan;
      2016   -   JPRN-UMIN000024086   Japan;
Prednisone
   AIDS Malignancy Consortium
      2002   Phase 2   NCT00041327   United States;
   National Cancer Institute (NCI)
      2020   Phase 1   NCT04301076   United States;
   Washington University School of Medicine
      2010   Phase 1/Phase 2   NCT01000285   United States;
Propantheline Bromide
   Hospital Universitário Professor Edgard Santos
      2012   Phase 1   NCT01640002   Brazil;
Raltegravir
   National Institute of Neurological Disorders and Stroke (NINDS)
      2013   Early Phase 1   NCT01867320   United States;
   Washington University School of Medicine
      2012   Phase 2   NCT01620736   United States;
      2010   Phase 1/Phase 2   NCT01000285   United States;
Raltegravir and Zidovudine
   Universidad Peruana Cayetano Heredia
      2017   Early Phase 1   NCT02655471   Peru;
Recombinant human interferon beta-1a
   National Institute of Neurological Disorders and Stroke (NINDS)
      1998   Phase 2   NCT00001785   United States;
Recombinant interferon alfa
   AIDS Malignancy Consortium
      2002   Phase 2   NCT00041327   United States;
Tamibarotene
   St. Marianna University School of Medicine
      2011   Phase 2/Phase 3   NCT01343355   Japan;
Teriflunomide
   National Institute of Neurological Disorders and Stroke (NINDS)
      2021   Phase 1/Phase 2   NCT04799288   United States;
Valproic acid
   University of Sao Paulo
      2008   Phase 3   NCT00681980   Brazil;
Valproid acid plus corticosteroids
   University of Sao Paulo
      2008   Phase 3   NCT00681980   Brazil;
Vincristine
   Washington University School of Medicine
      2010   Phase 1/Phase 2   NCT01000285   United States;
Vincristine Sulfate
   National Cancer Institute (NCI)
      2020   Phase 1   NCT04301076   United States;
Vincristine sulfate
   AIDS Malignancy Consortium
      2002   Phase 2   NCT00041327   United States;
Zidovudine
   AIDS Malignancy Consortium
      2002   Phase 2   NCT00041327   United States;
Zidovudine/lamivudine
   Imperial College London
      1999   Phase 2/Phase 3   NCT00272480   United Kingdom;